Kingston’s Spectra Plasmonics pilots rapid tests to find ‘fingerprints’ of toxic contaminants in street drugs

As the opioid crisis continues to take lives in big cities and small communities across Canada, a Kingston technology company has developed a rapid testing system to identify the lethal contaminants sometimes present in street drugs.

Spectra Plasmonics’ drug analysis system identifies the unique chemical “fingerprints” of various substances found in a sample and can detect the presence of dangerous contaminants such as fentanyl.

The technology is currently being piloted at a supervised consumption site in Kingston, but company officials say they’re eager to roll out the devices across North America.

“We want this to be in the hands of everybody whose job it is to save lives in this crisis,” says company co-founder and CEO Malcolm Eade.

Learn more about Spectra Plasmonics by watching the full interview with Eade above.